BRIEF—Sawai extends label for generic Abilify

Osaka, Japan-based firm Sawai Pharmaceutical has successfully extended the label for aripiprazole in Japan, to include manic episodes associated with bipolar disorder.

Aripiprazole is a generic version of Otsuka’s schizophrenia therapy, marketed as Abilify.

Founded in 1929, Sawai Pharmaceutical acquired US-based Upsher-Smith Laboratories in 2017, marking its first step in a strategy of overseas expansion.